Ensysce BiosciencesENSC
ENSC
About: Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Employees: 8
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
97% more capital invested
Capital invested by funds: $581K [Q3] → $1.15M (+$565K) [Q4]
10.66% less ownership
Funds ownership: 21.41% [Q3] → 10.75% (-10.66%) [Q4]
38% less funds holding
Funds holding: 13 [Q3] → 8 (-5) [Q4]
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for ENSC.
Financial journalist opinion
Based on 6 articles about ENSC published over the past 30 days
Neutral
Accesswire
6 days ago
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 630,376 shares of common stock of the Company originally issued in March 2025, having an exercise price of $3.24 per share. The shares of common stock issued upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No.
Neutral
Accesswire
6 days ago
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 630,376 shares of common stock of the Company originally issued in March 2025, having an exercise price of $3.24 per share. The shares of common stock issued upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No.
Positive
Benzinga
1 week ago
Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why
Ensysce Biosciences, Inc ENSC stock gained almost 100% with a strong session volume compared to the average volume of 81.23K, as per data from Benzinga Pro.
Neutral
Accesswire
1 week ago
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 630,376 shares of common stock of the Company originally issued in March 2025, having an exercise price of $3.24 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No.
Neutral
Accesswire
1 week ago
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~ ~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled: Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof¹ including both composition of matter and method of use claims. PF9001, the innovative medication covered by this patent, is designed to provide a safer treatment option for opioid use disorder (OUD) by using Ensysce's TAAPTM and MPAR® abuse deterrent and overdose protection technologies.
Neutral
Accesswire
2 weeks ago
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~ SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced completion of Part 1 of its second clinical trial to evaluate PF614-MPAR for overdose protection. PF614-MPAR-102 demonstrated that the combined Ensysce TAAPTM and MPAR® technologies can deliver strong relief for severe pain yet protect from the risk of excessive doses when consumed accidentally or deliberately.
Neutral
Accesswire
1 month ago
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with an aggregate gross proceeds of approximately $1.1 million, for the issuance and sale of an aggregate of 315,188 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $3.49 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company has also agreed to issue and sell unregistered Series A-5 warrants to purchase up to an aggregate of 315,188 shares of common stock and unregistered Series A-6 warrants to purchase up to an aggregate of 315,188 shares of common stock.
Neutral
Accesswire
1 month ago
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, announced it will host a symposium on Wednesday, September 3, 2025, during PAINWeek 2025, designed to share perspectives with experts in the field of pain management. In preparation for this meeting, the company recently hosted a panel discussion entitled "The State of the Nation in Pain: A Discussion on Analgesics and Their Optimal Uses".
Neutral
Accesswire
1 month ago
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the fourth quarter and full year ended December 31, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our team continued to make significant strides in the fourth quarter to deliver what we believe are the ‘Next Generation' opioid analgesics with both abuse and overdose protection.
Neutral
Accesswire
1 month ago
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA. Ensysce's Chief Executive Officer Dr. Lynn Kirkpatrick, Chief Financial Officer Dave Humphrey, and Chief Commercial Officer Geoff Birkett will be available to host one-on-one meetings with investors during the event.
Charts implemented using Lightweight Charts™